Lanitop (Metildigoxin)

Metildigoxin inhibits the Na⁺/K⁺‑ATPase pump on cardiac cells, leading to increased intracellular sodium. This change reduces calcium extrusion, raising intracellular calcium levels, which strengthens myocardial contraction and prolongs AV‑node refractory period, thereby slowing ventricular response in atrial tachyarrhythmias.

The appropriate dose of Lanitop is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, electrolyte status and therapeutic response. Dose titration is guided by clinical assessment and, when appropriate, serum drug concentration monitoring.

Safety data for Metildigoxin in pregnancy and lactation are limited. Because cardiac glycosides can cross the placenta and appear in breast milk, the drug is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To request Lanitop, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to Metildigoxin is digoxin, another cardiac glycoside. Both share a similar mechanism of action, but Metildigoxin may have a slightly different pharmacokinetic profile and potency. Choice between them depends on local regulatory status, clinician experience and individual patient response.

Lanitop tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Lanitop is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional.

The most serious risks include cardiac arrhythmias such as ventricular tachycardia, severe bradycardia, and heart block. Signs of toxicity—such as visual disturbances, nausea, vomiting, or palpitations—should prompt immediate medical evaluation.

Lanitop is contraindicated in patients with known hypersensitivity to Metildigoxin, uncontrolled ventricular arrhythmias, severe sinus node dysfunction without a pacemaker, and in those with significant electrolyte disturbances (especially hyperkalemia) that have not been corrected.